Immunitybio Action
ActionActionPrix
Questions fréquentes
Quelle est la capitalisation boursière de Immunitybio ?
Quel est le bénéfice par action (BPA) de Immunitybio ?
Quelles sont les évaluations des analystes et le prix cible de l'action Immunitybio ?
Quel est le chiffre d'affaires de Immunitybio sur les douze derniers mois ?
Quel est l'EBITDA de Immunitybio ?
Quel est le flux de trésorerie disponible de Immunitybio ?
Quel est le bêta à 5 ans de l'action Immunitybio ?
Combien d'employés compte Immunitybio, et à quel secteur d'activité appartient-elle ?
Quel est le flottant des actions de Immunitybio ?
Finances
Capitalisation boursière
3,37 Md $USbêta sur 5 ans
0,74BPA (TTM)
-0,867 $USFree Float
159,61 MRecettes (TTM)
7,33 M $USEBITDA (TTM)
-340,77 M $USCash-flow disponible (TTM)
-434,10 M $USCotation
Notes des analystes
L'objectif de prix est de 7,50 $US et l'action est analysée par 2 analystes.
Acheter
1
Hold
1
Vendre
0
Informations
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.
672
Biotechnology & Drugs
Soins de santé
Identifiant
ISIN
Ticker primaire